Questcor Pharmaceuticals (Nasdaq: QCOR) is good at making enemies. However, the company is also good at destroying them.
Today's Questcor finds itself the target of another negative blog post. This one from the king of short-selling blogs - Citron Research - which has an impressive track record being right with their negative views on individual stocks that they cover.
Citron has posted a 22-page report on Questcor with nasty comments like "snake oil salesmen," "single digit stock in 18 months."
Citron filed a Freedom of Information Act request and has obtained the FDA's approval history on ACTH, which they said "completely negate the "barrier to entry" claims of Questcor's CEO."
Market Data 
Markets 
AI
